Weekly Roundup for JANUARY 6, 2023: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
No Link Between Prenatal Exposure to Antidepressants and Risk for ADHD in Offspring
Consistent with other studies, including a large meta-analysis, this study indicates no increased risk of ADHD in offspring following prenatal exposure to antidepressants.
Still Not Enough Data on the Reproductive Safety of Oxcarbazepine (Trileptal)
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
Weekly Roundup for DECEMBER 30, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Prenatal Exposure to Topiramate (Topamax):Â Impact on Neurodevelopmental Outcomes
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.